RE: Afternoon all27 Oct 2025 17:44
I think the board are very dussapiinted in the current market cap at £3M.They were stating Lyramid deal at 10.8M dollars and Oncogeni at 12.8M.
Coiled now want Stat6 which was part of Oncogni so no carveout for that.Lyramid going to the wire and if it doesn't proceed then I guess that shall be included in the rto.There was a cash upfront max 2M dollars.
They need the rto to complete to progress the existing company.
We still could get Lyramid over the line,I'm sure we shall hear something tomorrow however if another extension for 2 months that kind of Co.plicate matters..
They have to submit admission document,they were hoping after the Lyramid deal,then they would suspend,delist off the main. Market and resistant on Aim Jan Feb next year.
The issue here is the strike price for the £30M which has to be paid to A2A,
One would hope that would reflect the cap of Roq plus the £30M..
Could go 3 ways
1. 3bn at 1p
2 1.5Bn at 2p
3.1bn at 3p
I think many thought Lyramid and Oncogni deals would multibag the shareprice,this didn't happen as they failed to get these over the line.
As far as A2A are concerned they're not bothered as long as they get their £3O M.
This is all very complicated and all the delays and silence on Oncogeni has put off retail.
Let's see what happens